AKUS Notícias Sobre o Forex
Akouos Says FDA Clears IND Application For AK-OTOF For OTOF-mediated Hearing Loss
Genetic medicine company Akouos, Inc. (AKUS) announced Tuesday that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1/2, first in human, pediatric clinical trial of AK-OTOF, a gene therapy intended for the treatment of patients with otoferlin gene (OTOF)-mediated hearing loss.
RTTNews
|
853 dias atrás
